Ulcerative Colitis Target Patient Analysis
Ulcerative Colitis Target Patient Analysis breaks down the unique aspects of eight branded UC products amongst UC patients. The target ulcerative colitis patient for each drug differs from one another, but some also share similarities among surveyed gastroenterologists. The report describes those differences and each brand’s unique emotional perceptions.
Between disease severity, treatment history, lifestyle choices, and much more, UC patients will have different perspectives on treatment options and the brands that coincide with those. As newly launched brands and pipeline treatments try to understand and work with the target UC patient, it’s helpful to understand the backgrounds of those patients and their perceptions of each existing brand.
Multiple categories make up the ‘typical’ UC patient. This report shows how each brand preforms with different types of UC patients and how the patient population is broken down based on their unique needs. With a thorough analysis of the target ulcerative colitis patient and how gastroenterologists make their treatment decisions, this strategy guide is an invaluable tool to inform any ulcerative colitis brand’s marketing plan.
Overview of Ulcerative Colitis Patient Analysis
US gastroenterologists approach each ulcerative colitis brand differently depending on a set of patient characteristics. Ulcerative Colitis Target Patient Analysis shows how each gastroenterologist and UC patient decide which branded ulcerative colitis medication is best for their unique situation. These UC patient aspects give insight into why gastroenterologists make their treatment decisions.
The report focuses on how US gastroenterologists’ and UC patients react to branded UC medications based on details in a patient’s life such as:
- Disease severity
- Treatment history
- Lifestyle
- Adherence
- Comorbidities
Branded Treatments Analyzed
- Entyvio
- Humira
- Remicade
- Simponi
- Stelara
- Uceris
- Xeljanz
- Zeposia
Strategic Questions Answered within Ulcerative Colitis Target Patient Analysis
- Treatment Drivers: What are the key patient characteristics that drive HCP prescription decisions among UC treatments?
- Brand Ownership: What characteristics define the ‘typical’ patient receiving current UC treatments?
- Patient Segments: What are the most common UC patient archetypes that shape how HCPs make prescription decisions?
Summary of Strategic Insights found in Ulcerative Colitis Target Patient Analysis
- For patients who need a new UC treatment either because their disease has progressed to a moderate to severe state or because they have failed a biologic, Entyvio is a near-ideal solution.
- Oral therapies Xeljanz and Zeposia provide HCPs with an oral medication for moderate UC patients who have failed at least one biologic and who have no comorbidities.
- Humira continues to provide Gastros with a frequently used first-line option to treat moderate UC patients who lead a very active lifestyle but have yet to try a biologic treatment.
Benefits of Purchasing Ulcerative Colitis Target Patient Analysis
- Cost-efficient analysis about UC patient trends to support your strategic marketing decisions.
- Insights drawn from in-depth interviews among global KOLs and surveys of more than 125 gastroenterologists
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s ulcerative colitis strategist for 1-year.
Table of Contents
Executive Summary – 6
- Research Methodology: Robust Insights from US Gastroenterologists – 7
- The Strategic Six: Key Insights About Target Patients for UC Brands – 8
- ‘Typical’ Patient Map – 9
UC Brand Target Patient Profiles – 10
- Patient Share by Ulcerative Colitis Treatment – 11
- 12-month Prescribing Trends – 12
- Entyvio ‘Typical’ Patient Summary – 14
- Entyvio Patient ‘Typical’ Disease Severity – 15
- Entyvio Patient ‘Typical’ Treatment History – 16
- Entyvio Patient: ‘Typical’ Lifestyle – 17
- Entyvio Patient: ‘Typical’ Treatment Adherence – 18
- Entyvio Patient: ‘Typical’ Comorbidities – 19
- Remicade Patient ‘Typical’ Disease Severity – 22
- Remicade Patient ‘Typical’ Treatment History – 23
- Remicade Patient: ‘Typical’ Lifestyle – 24
- Remicade Patient: ‘Typical’ Treatment Adherence – 25
- Remicade Patient: ‘Typical’ Comorbidities – 26
- Humira ‘Typical’ Patient Summary – 28
- Humira Patient ‘Typical’ Disease Severity – 29
- Humira Patient ‘Typical’ Treatment History – 30
- Humira Patient: ‘Typical’ Lifestyle – 31
- Humira Patient: ‘Typical’ Treatment Adherence – 32
- Humira Patient: ‘Typical’ Comorbidities – 33
- Stelara ‘Typical’ Patient Summary – 35
- Stelara Patient ‘Typical’ Disease Severity – 36
- Stelara Patient ‘Typical’ Treatment History – 37
- Stelara Patient: ‘Typical’ Lifestyle – 38
- Stelara Patient: ‘Typical’ Treatment Adherence – 39
- Stelara Patient: ‘Typical’ Comorbidities – 40
- Uceris ‘Typical’ Patient Summary – 42
- Uceris Patient ‘Typical’ Disease Severity – 43
- Uceris Patient ‘Typical’ Treatment History – 44
- Uceris Patient: ‘Typical’ Lifestyle – 45
- Uceris Patient: ‘Typical’ Treatment Adherence – 46
- Uceris Patient: ‘Typical’ Comorbidities – 47
- Xeljanz ‘Typical’ Patient Summary – 49
- Xeljanz Patient ‘Typical’ Disease Severity – 50
- Xeljanz Patient ‘Typical’ Treatment History – 51
- Xeljanz Patient: ‘Typical’ Lifestyle – 52
- Xeljanz Patient: ‘Typical’ Treatment Adherence – 53
- Xeljanz Patient: ‘Typical’ Comorbidities – 54
- Zeposia ‘Typical’ Patient Summary – 56
- Zeposia Patient ‘Typical’ Disease Severity – 57
- Zeposia Patient ‘Typical’ Treatment History – 58
- Zeposia Patient: ‘Typical’ Lifestyle – 59
- Zeposia Patient: ‘Typical’ Treatment Adherence – 60
- Zeposia Patient: ‘Typical’ Comorbidities – 61
- Simponi ‘Typical’ Patient Summary – 63
- Simponi Patient ‘Typical’ Disease Severity – 64
- Simponi Patient ‘Typical’ Treatment History – 65
- Simponi Patient: ‘Typical’ Lifestyle – 66
- Simponi Patient: ‘Typical’ Treatment Adherence – 67
- Simponi Patient: ‘Typical’ Comorbidities – 68
Entyvio Patient Profile – 13
Remicade Patient Profile – 13
Humira Patient Profile – 27
Stelara Patient Profile – 34
Uceris Patient Profile – 41
Xeljanz Patient Profile – 48
Zeposia Patient Profile – 55
Simponi Patient Profile – 62
UC Prescription Trends in Patient Sub-groups – 69
- Disease Severity: Mild Patient Trends – 71
- Disease Severity: Mild to Moderate Patient Trends – 72
- Disease Severity: Moderate Patient Trends – 73
- Disease Severity: Moderate to Severe Patient Trends – 74
- Disease Severity: Severe Patient Trends – 75
- Treatment History: Biologic Naïve – 77
- Treatment History: Failed One Biologic – 78
- Treatment History: Failed Two Biologics – 79
- Treatment History: Failed Three or More Biologics – 80
- Lifestyle: Very Active and Busy – 82
- Lifestyle: Moderately Active – 83
- Lifestyle: Less Active or Sedentary – 84
- Treatment Adherence: Strong Compliance with Treatment – 86
- Treatment Adherence: Moderate Compliance with Treatment – 87
- Treatment Adherence: Poor Compliance with Treatment – 88
- Rx Trends by Comorbidities – 89
- Comorbidities: Good Health with Few or No Comorbidities – 90
- Comorbidities: Moderate Health with Some Comorbidities – 91
- Comorbidities: Poor Health with Multiple Comorbidities – 92
